Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gustavo Laham is active.

Publication


Featured researches published by Gustavo Laham.


Transplantation Proceedings | 2010

Conversion to Sirolimus Allows Preservation of Renal Function in Kidney and Kidney–Pancreas Allograft Recipients

Gustavo Laham; S. Sleiman; G. Soler Pujol; Carlos Guerrero Díaz; M. Dávalos; Antonio Vilches

The major causes of graft failure are chronic allograft nephropathy (CAN) and patient mortality. Sirolimus (SRL) is a powerful immunosuppressant with a less nephrotoxic profile as well as a lower incidence of cancer. The aim of this study was to evaluate the impact of conversion to SRL from calcineurin inhibitor (CNI)-based therapy in kidney (KT) and kidney-pancreas (SPK) allograft recipients. We analyzed renal function, allograft and patient survival, and SRL-associated adverse effects in 93 adult patients (86 KT and 7 SPK), who were converted to SRL between January 2001 and November 2008. The main reason for conversion was CAN (76; 9%) and 52 (7%) were receiving tacrolimus. Conversion occurred at a median 26.2 months. There was a significant improvement in creatinine clearance (CCr) at 6 months after conversion (CCr(baseline) 51.4 vs CCr(6m) 60.4 mL/min; P < .0001), without changes at 12 and 24 months. However, proteinuria increased significantly at 6 months compared with the baseline: 150 mg/24 hours (0-453) versus 0 mg/24 hours (range, 0-309), respectively (P < .0001), but did not progress at 12 or 24 months. At the same time we observed more extensive use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: 60/5%; 65/3% and 70/2% at 6, 12, and 24 months. There were no changes in blood pressure control. Cholesterol significantly increased at 6 months (218.2 +/- 37 vs. 186.6 +/- 44 mg/dL; P < .0001). Graft and patient survivals at 4 years were 88% and 95%, respectively. Our experience suggested that conversion to SRL constituted a safe alternative with excellent results in patient and graft survival.


Transplantation | 2017

Nonprogrammed Vascular Access Is Associated With Greater Mortality in Patients Who Return to Hemodialysis With a Failing Renal Graft

Gustavo Laham; Gervasio Soler Pujol; Antonio Vilches; Ana Cusumano; Carlos Guerrero Díaz

Background In incident hemodialysis (HD) patients, the use of catheters is associated with a worse prognosis when compared with those with an arteriovenous fistula, but the role of vascular access (VA) type in the morbidity and mortality of patients returning to HD with a failing renal allograft is unknown. We aimed to determine the associations between the type of VA and mortality in this population. Methods This was a retrospective observational cohort study of 138 patients who initiated dialysis after kidney transplant failure between 1995 and 2014. We recorded access type, laboratory values at entry, stratified patients per risk, and determined the effect on mortality of programmed VA (PVA), (arteriovenous fistula or PTFE graft) and nonprogrammed VA (UPVA) (tunneled or nontunneled catheters) at the initiation of HD. Results Eighty-five (61.6%) and 53 (38.4%) patients initiated therapy with PVA and UPVA, respectively. Overall mortality was 14.6% at 1 year. Patients using catheters had greater mortality than those with a PVA (log rank P <0.0001). At 24 months, 7 patients died in PVA group versus 22 in UPVA group. Multivariate Cox analysis showed that initiation of HD with a catheter (hazard ratio, 5.90; 95%, confidence interval, 2.83-12.31) was independently associated with greater mortality after adjusting for confounders. Conclusions Nonprogrammed VA with a catheter predicted all-cause mortality among patients with transplant failure reentering HD.


Clinical Transplantation | 2014

Travel for transplantation and transplant commercialism in Argentina: a 4-decade experience from a University Hospital

Ezequiel Rodríguez‐Reimundes; Gervasio Soler‐Pujol; Carlos Díaz; Mario Dávalos‐Michel; Luis Jost; Gustavo Laham; Antonio Vilches


Transplantation Proceedings | 2016

Surveillance Registry of Sirolimus Use in Recipients of Kidney Allografts From Expanded Criteria Donors

Gustavo Laham; R. Scuteri; P. Cornicelli; M. Arriola; P.M. Raffaele; M. Dávalos Michel; Nora Imperiali; R.M. Fortunato; E.C. Maggiora; M.V. Sal; G. Soler Pujol


Transplantation | 2018

Immunologic and Histologic Monitoring after Renal Transplantation a Single Center Experience.

Gervasio Soler Pujol; Gustavo Laham; Anabel Abib; Jihan Sleiman; Marcela Quintana; Sara Teper; Roberto Iotti; Carlos Guerrero Díaz


Nephrology Dialysis Transplantation | 2018

SP412HANDGRIP STRENGTH PREDICTORS IN HEMODIALYSIS PATIENTS

Carlos Matías Callegari; Mauro Magenta; Gustavo Laham; Carlos Castellaro; Lucila Carosella; Ines Baek; Carlos Guerrero Díaz


Revista De Nefrologia Dialisis Y Trasplante | 2017

Congreso de la Sociedad Americana de Nefrología: San Diego EEUU

Gustavo Laham


Revista De Nefrologia Dialisis Y Trasplante | 2017

Incidencia e impacto de Injuria Renal Aguda comunitaria e intrahospitalaria en un Hospital Universitario de Buenos Aires

Carlos Matías Callegari; Rodríguez Pablo; Gustavo Laham; Carlos Guerrero Díaz


Nephrology Dialysis Transplantation | 2017

SP573PREDICTORS OF VASCULAR RESISTANCE INCREASE IN PATIENTS IN DIALYSIS

M. Schiavone; María Elena Biaiñ; Gustavo Laham; Carlos Guerrero Díaz; Gaston Fernandez Candia; Fernando Speranzoni; Juan Montagnana; Redondo Pereira; Felipe Inserra; Carlos Castellaro


Nephrology Dialysis Transplantation | 2017

SP568DETERMINANTS OF ORTHOSTATIC HYPOTENSION IN DIALYSIS PATIENTS

Biain Maria Elena; M. Schiavone; Carlos Castellaro; Mauro Magenta; Gaston Fernandez Candia; Carlos Calegari; Carlos Guerrero Díaz; Fernando Speranzoni; Juan Montagnana; S. Gonzalez; Felipe Inserra; Gustavo Laham

Collaboration


Dive into the Gustavo Laham's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel Noli

Fresenius Medical Care

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge